EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 6522 participants.

Also called NCT04509674

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 6,522 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04509674
  • EudraCT 2019-001037-13
Other papers using this trial's data
  • Effect of Empagliflozin on Heart Failure Outcomes After Acute Myocardial Infarction: Insights From the EMPACT-MI Trial Circulation, 2024-05-21 DOI, PubMed 38581389, PMC11115458 In the PMC Open Access subset under CC BY.
  • Empagliflozin after Acute Myocardial Infarction The New England journal of medicine, 2024-04-25 DOI, PubMed 38587237
  • Left Ventricular Function, Congestion, and Effect of Empagliflozin on Heart Failure Risk After Myocardial Infarction Journal of the American College of Cardiology, 2024-06-11 DOI, PubMed 38588929

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Australia, Brazil, Bulgaria, Canada, China, Denmark, France, Germany, Hungary, India, Israel, Japan, Netherlands, Poland, Romania, Russia, Serbia, South Korea, Spain, Ukraine (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04509674. Randomized; quadruple masking; primary purpose treatment. Start 2020-12-16 (actual); primary completion 2023-11-05 (actual). Results posted on 2025-01-07.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction)
Intervention (Drug)
Empagliflozin
Intervention (Drug)
Placebo
Lead sponsor
Boehringer Ingelheim (class: industry)
Collaborator
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct04509674
Content hash
5095dba731800a7827c8a40824c700817c5fa56a869f9620948624416077891b